Biodegradable nano-architectural PEGylated approach for the improved stability and anticancer efficacy of bendamustine

International Journal of Biological Macromolecules

Volumn 92, Issue , 2016, Pages 1242-1251

  Khan, Iliyas ^a   Gothwal, Avinash ^a   Sharma, Ashok Kumar ^a   Qayum, Arem ^b   Singh, Shashank K ^b   Gupta, Umesh ^a  

^a CENTRAL UNIVERSITY OF RAJASTHAN   (India)

^b CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

Author keywords

Bendamustine; Nanoparticles; PEG PLGA conjugate; PLGA nanoparticles

Indexed keywords

BENDAMUSTINE; COPOLYMER; NANOCONJUGATE; POLYETHYLENE GLYCOL POLYLACTIDE CO GLYCOLIDE COPOLYMER; POLYGLACTIN; UNCLASSIFIED DRUG; ALKYLATING AGENT; DRUG CARRIER; MACROGOL DERIVATIVE; NANOPARTICLE; POLYESTER; POLYETHYLENE GLYCOL-POLY(LACTIDE-CO-GLYCOLIDE);

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIODEGRADABILITY; BLOOD TOXICITY; BREAST CANCER CELL LINE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG STABILITY; ENTRAPMENT EFFICIENCY; EX VIVO STUDY; HEMOLYSIS ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED SPECTROSCOPY; KINETICS; MALE; MCF 7 CELL LINE; NANOANALYSIS; NANOFABRICATION; NORMAL HUMAN; PARTICLE SIZE; PC 3 CELL LINE; PHARMACOLOGICAL PARAMETERS; POLYDISPERSITY INDEX; PROSTATE CANCER CELL LINE; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION OPTIMIZATION; SCANNING ELECTRON MICROSCOPY; SUSTAINED DRUG RELEASE; SYNTHESIS; T47D CELL LINE; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG FORMULATION; DRUG RELEASE; ERYTHROCYTE; FEMALE; HEMOLYSIS; MCF-7 CELL LINE; TUMOR CELL LINE; ULTRASTRUCTURE;

ANTINEOPLASTIC AGENTS, ALKYLATING; BENDAMUSTINE HYDROCHLORIDE; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; DRUG COMPOUNDING; DRUG LIBERATION; DRUG STABILITY; ERYTHROCYTES; FEMALE; HEMOLYSIS; HUMANS; KINETICS; MALE; MCF-7 CELLS; NANOPARTICLES; PARTICLE SIZE; POLYESTERS; POLYETHYLENE GLYCOLS;

EID: 84982136506     PISSN: 01418130     EISSN: 18790003     Source Type: Journal    
DOI: 10.1016/j.ijbiomac.2016.08.004     Document Type: Article

References (33)

1. [1] Cheson, B.D., Leoni, L., Bendamustine: mechanism of action and clinical data. Clin. Adv. Hematol. Oncol. 9 (2011), 1–11.
2. [2] Ploskar, G.L., Carter, N.J., Bendamustine a review of its use in the management of indolent non-Hodgkin lymphoma. Adis Drug Eval. 68 (2008), 2645–2660.
3. [3] Evjen, T.L., Development of improved bendamustin-liposomes. 2007, Institute of Pharmacy, Faculty of Medicine University of Tromsø, 1–92.
4. [4] Leong, H., Bonk, M.E., Bendamustine (Treanda) for chronic lymphocytic leukaemia. Drug Forecast 34 (2009), 73–76.
5. [5] Zhang, Y., Chan, H.F., Leong, K.W., Advanced material and processing for drug delivery: the past and future. Adv. Drug Deliv. Rev. 65 (2013), 104–120.
6. [6] Dinarvand, R., Sepehri, N., Manoochehri, S., Rouhani, H., Atyabi, F., Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int. J. Nanomed. 6 (2011), 877–895.
7. [7] Gothwal, A., Khan, I., Gupta, U., Polymeric micelles: recent advancements in the delivery of anti-cancer drugs. Pharm. Res. 33:1 (2016), 18–39.
8. [8] Venkataraman, S., Hedrick, J.L., Ong, Z.Y., Yang, C., Ee, P.L.R., Hammond, P.T., Yang, Y.Y., The effects of polymeric nanostructure shape on drug delivery. Adv. Drug Deliv. Rev. 63 (2011), 1228–1246.
9. [9] Mirakabad, F.S.T., Nejati-Koshki, K., Akbarzadeh, A., Yamchi, M.R., Milani, M., Zarghami, N., Zeighamian, V., Rahimzadeh, A., Alimohammadi, S., Hanifehpour, Y., Joo, S.W., PLGA-based nanoparticles as cancer drug delivery systems. Asian Pac. J. Cancer Prev. 15 (2014), 517–535.
10. [10] Brannon-Peppas, L., Blanchette, J.O., Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 64 (2012), 206–212.
11. [11] Danhier, F., Ansorena, E., Silva, J.M., Coco, R., Breton, A.L., Preat, V., PLGA-based nanoparticles: an overview of biomedical applications. J. Control. Release 161 (2012), 505–522.
12. [12] Acharya, S., Sahoo, S.K., PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv. Drug Deliv. Rev. 63 (2011), 170–183.
13. [13] Vasir, J.K., Labhasetwar, V., Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv. Drug Deliv. Rev. 59 (2007), 718–728.
14. [14] Owens, D.E. III, Peppas, N.A., Opsonization bio-distribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307 (2006), 93–102.
15. [15] Banerjee, S.S., Aher, N., Patil, R., Khandare, J., Poly (ethylene glycol)-prodrug conjugates: concept, design, and applications. J. Drug Deliv., 2012, 1–17.
16. [16] Kojima, C., Regino, C., Umeda, Y., Kobayashi, H., Kono, K., Influence of dendrimer generation and polyethylene glycol length on the bio-distribution of PEGylated dendrimers. Int. J. Pharm. 383 (2010), 293–296.
17. [17] Cheng, J., Teply, B.A., Sherifi, I., Sung, J., Luther, G., Gu, F.X., Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28 (2007), 869–876.
18. [18] Gupta, M., Chashoo, G., Sharma, P.R., Saxena, A.K., Gupta, P.N., Agarwal, G.P., Vyas, S.P., Dual targeted polymeric nanoparticles based on tumor endothelium and tumor cells for enhanced antitumor drug deliver. Mol. Pharm. 11 (2014), 697–715.
19. [19] Pencheva, E., Bogomilova, A., Koseva, N., Obreshkova, D., Troev, K., HPLC study on the stability of bendamustine hydrochloride immobilized onto polyphosphoesters. J. Pharm. Biomed. Anal. 48 (2008), 1143–1150.
20. [20] Costa, P., Lobo, J.M.S., Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 13 (2001), 123–133.
21. [21] Dash, S., Murthy, P.N., Nath, L., Chowdhury, P., Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol. Pharm. Drug Res. 67 (2010), 217–223.
22. [22] Tang, X., Liang, Y., Feng, X., Zhang, R., Jin, X., Sun, L., Co-delivery of docetaxel and poloxamer 235 by PLGA-TPGS nanoparticles for breast cancer treatment. Mater. Sci. Eng. C 49 (2015), 348–355.
23. [23] Singhai, A.K., Jain, S., Jain, N.K., Evaluation of an aqueous injection of Ketoprofen. Pharmazie 52 (1997), 149–151.
24. [24] Agarwal, P., Gupta, U., Jain, N.K., Glycoconjugated peptide dendrimers-based nanoparticulate system for the delivery of chloroquine phosphate. Biomaterials 28 (2007), 3349–3359.
25. [25] Pachauri, M., Gupta, E.D., Ghosh, P.C., Piperine loaded PEG-PLGA nanoparticles: preparation, characterization and targeted delivery for adjuvant breast cancer chemotherapy. J. Drug Deliv. Sci. Technol. 29 (2015), 269–282.
26. [26] Suo, A., Qian, J., Zhang, Y., Liu, R., Xu, W., Wang, H., Comb-like amphiphilic polypeptide-based copolymer nanomicelles for co-delivery of doxorubicin and P-gp siRNA into MCF-7 cells. Mater. Sci. Eng. C 62 (2016), 564–573.
27. [27] Zhang, W., Zheng, X., Shen, S., Wang, X., Doxorubicin-loaded magnetic nanoparticle clusters for chemophotothermal treatment of the prostate cancer cell line PC3. Biochem. Biophys. Res. Comm. 466 (2015), 278–282.
28. [28] Lee, A.L.Z., Wang, Y., Cheng, H.Y., Pervaiz, S., Yang, Y.Y., The co-delivery of paclitaxel and herceptin using cationic micellar nanoparticles. Biomaterials 30 (2009), 919–927.
29. [29] Mosamann, T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Imunol. Methods 65 (1983), 55–63.
30. [30] Wang, H., Zhao, Y., Wu, Y., Hu, Y.L., Nan, K., Nie, G., Chen, H., Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 32 (2011), 8281–8290.
31. [31] Singh, P., Gupta, U., Asthana, A., Jain, N.K., Folate and folate-PEG-PAMAM dendrimers: synthesis, characterization and targeted anticancer drug delivery potential in tumor induced mice. Bioconjug. Chem. 19:19 (2008), 2239–2252.
32. [32] Scutaru, A.M., Wenzel, M., Scheffler, H., Wolber, G., Gust, R., Optimization of the N-lost drugs melphalan and bendamustine: synthesis and cytotoxicity of a new set of dendrimer-drug conjugates as tumor therapeutic agents. Bioconjug. Chem. 21 (2010), 1728–1743.
33. [33] Eichbaum, M.H.R., Schuetz, F., Khbeis, T., Lauschner, I., Foerster, F., Sohn, C., Schneeweiss, A., Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study. Anticancer Drugs 18 (2007), 963–968.